Soleno reports Q2 2024 net loss of $21.9M; NDA for DCCR in PWS submitted to FDA

SOLENO THERAPEUTICS INC

2024-Q2 EPS reported -$1.16

NDA for Diazoxide Choline Extended-Release (DCCR) for Prader-Willi Syndrome with hyperphagia submitted to FDA.
Cash, cash equivalents and marketable securities of $294.6M as of June 30, 2024.
Net loss of $21.9M ($0.57 per share) for Q2 2024 vs. $8.5M ($0.81 per share) in Q2 2023.
R&D expense $12.3M (Q2 2024) up from $5.1M (Q2 2023) due to NDA submission and launch prep.
Closed $158.7M public offering of 3.45M shares at $46.00 each; BT designation for DCCR granted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.